1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. アレルギータイプ別スニペット
3.2. 治療タイプ別スニペット
3.3. 販売チャネル別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 世界的なアレルギーの有病率の増加
4.1.2. 阻害要因
4.1.2.1. 投薬に伴う副作用
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
5.5. アンメット・ニーズ
5.6. PESTEL分析
5.7. 特許分析
5.8. SWOT分析
6. アレルギータイプ別
6.1. はじめに
6.1.1. アレルギータイプ別市場規模分析および前年比成長率分析（%） 6.1.2.
6.1.2. 市場魅力度指数、アレルギータイプ別
6.2. 眼アレルギー
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.3. 食物アレルギー
6.4. 皮膚アレルギー
6.5. 喘息
6.6. 鼻炎
6.7. その他
7. 治療タイプ別
7.1. はじめに
7.1.1. 治療タイプ別市場規模分析および前年比成長率分析（%） 7.1.2.
7.1.2. 市場魅力度指数（治療タイプ別
7.2. 抗アレルギー薬*市場
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 免疫療法
8. 流通チャネル別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
8.1.2. 市場魅力度指数（流通チャネル別
8.2. 病院薬局
8.2.1. 序論
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. 小売薬局
8.4. オンライン薬局
8.5. その他
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（%）、アレルギータイプ別
9.2.4. 市場規模分析およびYoY成長率分析（%）、治療タイプ別
9.2.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析およびYoY成長率分析（%）、アレルギータイプ別
9.3.4. 市場規模分析およびYoY成長率分析（%）、治療タイプ別
9.3.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.3.6. 市場規模分析および前年比成長率分析（%）, 国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. イタリア
9.3.6.5. スペイン
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（%）、アレルギータイプ別
9.4.4. 市場規模分析およびYoY成長率分析（%）、治療タイプ別
9.4.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.4.6. 市場規模分析および前年比成長率分析（%）, 国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析（%）、アレルギータイプ別
9.5.4. 市場規模分析およびYoY成長率分析（%）、治療タイプ別
9.5.5. 市場規模分析および前年比成長率分析（%）：流通チャネル別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析およびYoY成長率分析（%）、アレルギータイプ別
9.6.4. 市場規模分析およびYoY成長率分析（%）、治療タイプ別
9.6.5. 市場規模分析および前年比成長率分析 (%)、流通チャネル別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. GlaxoSmithKline plc *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Teva Pharmaceutical Industries Ltd.
11.3. Stallergenes Greer
11.4. Allergy Therapeutics
11.5. Sanofi
11.6. Sumitomo Pharma Inc.
11.7. Johnson & Johnson Services Inc.
11.8. Merck & Co. Inc.
11.9. F.Hoffman -La Roche
11.10. Abbvie Inc.
リストは網羅的ではありません
12. 付録
12.1. 会社概要とサービス
12.2. お問い合わせ
The global allergy treatment market reached US$ 25.03 billion in 2023 and is expected to reach US$ 38.04 billion by 2031, growing at a CAGR of 5.4% during the forecast period 2024-2031.
Allergy is a hypersensitive reaction of the immune system to normally harmless chemicals known as allergens. These reactions arise when the immune system incorrectly perceives these harmless chemicals as threats, resulting in an excessive immunological response. Allergy treatment includes a number of treatments for managing symptoms and lowering the severity of allergic reactions. The primary approaches include allergen avoidance, usage of medication, and immunotherapy.
The increasing prevalence of allergies across the globe drives the market over the forecast period. Due to increasing prevalence, the demand for the treatment increases which propels the market. For instance, according to the Global Allergy and Airways Patient Platform, The global prevalence of allergy disorders is rapidly increasing in both developed and developing countries. The global prevalence of allergic disorders has steadily increased, with approximately 30-40% of the world's population now suffering from one or more allergic conditions.
Market Dynamics: Drivers
Increasing prevalence of allergies across the globe
The global allergy treatment market is majorly driven by the increasing prevalence of allergies. Allergic disorders are on the rise worldwide, including respiratory allergies (such as asthma and allergic rhinitis), food allergies, and skin allergies. This surge can be attributed to environmental causes such as increased pollution, urbanization, and lifestyle changes that expose people to more allergens.
Moreover, according to World Health Organization (WHO) statistics, hundreds of millions of people worldwide suffer from rhinitis, and more than 300 million are estimated to have asthma, reducing the quality of life for these people and their families and negatively impacting society's socioeconomic welfare. According to the American Academy of Allergy, Asthma & Immunology, Sensitization rates to one or more common allergens among schoolchildren worldwide are now approaching 40%-50%. Globally, 25.7% of persons aged 18 to 44 reported having a seasonal allergy.
Moreover, according to the World Allergy Organization Journal, allergic rhinitis, also known as hay fever, is a significant public health concern worldwide, affecting both developed and developing countries. Globally, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children. Due to the increasing prevalence of allergies, the demand for allergy treatment medication has increased and it drives the allergy treatment market.
Side effects associated with allergy treatment drugs
Factors such as side effects associated with allergy treatment drugs are expected to hamper the market. The antihistamines cause side effects such as drowsiness, dry mouth, blurred vision, difficulty urinating, headaches, dizziness, feeling sick, and diarrhea. The decongestants cause side effects such as trouble sleeping, headaches, increased blood pressure, and irritability. The majority of drug allergies are treatable, although they can occasionally cause severe asthma, anaphylaxis, or death. These side effects hamper the market and act as a restraint for the allergy treatment market.
Segment Analysis
The global allergy treatment market is segmented based on allergy type, treatment type, distribution channel, and region.
Allergy Type:
Asthma is expected to dominate the global allergy treatment market share.
The asthma segment holds a major portion of the global allergy treatment market share and is expected to continue to hold a significant portion of the global allergy treatment market share during the forecast period. The increasing prevalence of asthma makes asthma the most dominating segment in the global allergy treatment market. As the asthma prevalence increases, the demand for treatment medication increases and leads to market growth.
For instance, according to the Global Initiative for Asthma, Asthma is one of the most common chronic non-communicable diseases, affecting over 260 million people and accounting for over 450000 deaths annually worldwide, the majority of which are preventable.
Rhinitis segment is fastest growing segment in global allergy treatment market.
The rhinitis segment is the fastest-growing segment in the global allergy treatment market share during the forecast period. The gradual increase of rhinitis these days makes rhinitis the fastest-growing segment in the global allergy treatment market.
For instance, according to the World Allergy Organization Journal, allergic rhinitis affects more than 400 million people, with prevalence rates between 10% and 30% among adults and over 40% among children.
Treatment Type:
Anti-allergy drugs segment is expected to dominate the global allergy treatment market share.
The integrated monitoring systems segment holds a major portion of the global allergy treatment market share and is expected to continue to hold a significant portion of the global allergy treatment market share during the forecast period.
Anti-allergy drugs are used to treat symptoms caused by allergic reactions. These reactions happen when the immune system overreacts to normally harmless chemicals called allergens, which include pollen, pet dander, and certain foods. When an allergen is encountered, the immune system releases molecules like histamine, causing symptoms such as sneezing, itching, and nasal congestion. The anti-allergy drugs are expected to dominate the market due to their versatility and efficiency in reducing allergies.
Immunotherapy segment is the fastest growing segment in the global allergy treatment market share.
The immunotherapy features segment is the fastest growing segment in the global allergy treatment market share. The increasing awareness among people regarding immunotherapy and increased research activities make immunotherapy the fastest growing segment.
Immunotherapy has emerged as a key strategy in allergy treatment, with the goal of altering the immune system's response to allergens substances that cause allergic reactions. Unlike standard allergy drugs, which only treat symptoms, immunotherapy aims to target the root problem by gradually desensitizing the immune system to specific allergens.
For instance, in October 2024, Curex announced the launch of its unique at-home Sublingual Immunotherapy (SLIT) program for food allergies. This new service seeks to enable people with food allergies to safely and conveniently complete clinical desensitization at home.
Geographical Analysis
North America is expected to hold a significant position in the global allergy treatment market share.
North America region is expected to hold the largest market share over the forecast period. The rising incidence of chronic diseases, and recent launches, in this region, help to propel the market. The presence of top players, the increasing prevalence of allergies, and recent launches and approvals in the North American market helped to propel the market in this region.
For instance, in August 2024, The United States Food and Drug Administration (FDA) approved the first nasal spray for treating anaphylaxis, a severe and life-threatening allergic reaction that requires prompt medical attention, as well as an injection of epinephrine, a hormone shot that fights the allergen. The increasing prevalence of allergies is also one of the major driving factors. For instance, according to the American Academy of Allergy, Asthma & Immunology, roughly 7.8% of people 18 and over in the U.S. have hay fever.
Moreover, according to the American College of Allergy, Asthma & Immunology, asthma and allergic illnesses, such as allergic rhinitis (hay fever), food allergies, and eczema, affect people of all ages throughout the United States. Asthma affects more than 24 million individuals in the United States, including over 4.6 million children.
Asia Pacific is growing at the fastest pace in the global allergy treatment market
Asia Pacific region is expected to grow at the fastest pace over the forecast period. The increasing prevalence of allergies and increased research and development activities of various products help drive the market in this region.
For instance, according to the National Institute of Health, Asthma is estimated to affect 37.5 million people in India, and recent research shows that the prevalence of allergic rhinitis and asthma is increasing. Approximately 40-50% of pediatric asthma cases in India are uncontrolled or severe. Due to increases in allergies, the demand for allergy treatment is increasing day by day making this region the fastest-growing region in the forecast period.
Market Segmentation
By Allergy Type
• Eye Allergy
• Food Allergy
• Skin Allergy
• Asthma
• Rhinitis
• Others
By Treatment Type
• Anti-Allergy Drugs
o Antihistamines
o Corticosteroids
o Leukotriene Inhibitors
o Others
• Immunotherapy
o Subcutaneous Immunotherapy
o Sublingual Immunotherapy
By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the global allergy treatment market include GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Stallergenes Greer, Allergy Therapeutics, Sanofi, Sumitomo Pharma Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc. among others.
Emerging Players
Angany Inc., DBV Technologies, and Vedanta Biosciences, Inc. among others.
Key Developments
In February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure to one or more foods.
Why Purchase the Report?
• To visualize the global allergy treatment market segmentation based on allergy type, treatment type, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global allergy treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global allergy treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Allergy Type
3.2. Snippet by Treatment Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Allergies across the Globe
4.1.2. Restraints
4.1.2.1. Side Effects Associated with the Medication
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Allergy Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
6.1.2. Market Attractiveness Index, By Allergy Type
6.2. Eye Allergy*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Food Allergy
6.4. Skin Allergy
6.5. Asthma
6.6. Rhinitis
6.7. Others
7. By Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Anti-Allergy Drugs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Immunotherapy
8. By Distribution Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.1.2. Market Attractiveness Index, By Distribution Channel
8.2. Hospital Pharmacy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Allergy Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. GlaxoSmithKline plc *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Teva Pharmaceutical Industries Ltd.
11.3. Stallergenes Greer
11.4. Allergy Therapeutics
11.5. Sanofi
11.6. Sumitomo Pharma Inc.
11.7. Johnson & Johnson Services Inc.
11.8. Merck & Co. Inc.
11.9. F.Hoffman -La Roche
11.10. Abbvie Inc.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us
| ※参考情報 アレルギー治療は、アレルギー反応を軽減または防止するための医療行為を指します。アレルギーとは、体の免疫系が特定の物質に対して過剰に反応することです。この反応は、花粉、ダニ、食品、動物の毛、薬剤など、さまざまなアレルゲンによって引き起こされます。アレルギー症状は、鼻水、くしゃみ、皮膚のかゆみ、呼吸困難、消化器症状など多岐にわたり、生活の質を著しく低下させることがあります。 アレルギーの治療には、主に三つの方法があります。一つは回避療法で、アレルギーの原因となる物質を避けることです。例えば、花粉症の場合は、花粉が多い時期に外出を控える、室内の掃除をこまめに行う、エアコンのフィルターを清掃するなどの対策があります。 二つ目は薬物療法で、アレルギー症状を軽減するために使用される医薬品です。抗ヒスタミン薬、ステロイド剤、ロイコトリエン拮抗薬などが一般的に使われます。抗ヒスタミン薬は、アレルギー反応によって放出されるヒスタミンの作用をブロックし、くしゃみや鼻水、かゆみなどの症状を和らげます。ステロイド剤は、炎症を抑える働きがあり、重度のアレルギー反応の場合に使用されます。ロイコトリエン拮抗薬は、喘息やアレルギー性鼻炎の治療に用いられ、呼吸器の炎症を軽減します。 三つ目は免疫療法です。免疫療法は、アレルゲンを少量ずつ体に取り入れることで、免疫系を再教育し、アレルギー反応を鈍化させる治療法です。特に、スギ花粉やダニに対するアレルギーに有効とされています。皮下投与法や舌下投与法が一般的で、数か月から数年にわたって治療が行われます。 アレルギー治療の選択は、個々の症状や生活環境、アレルゲンの種類、重症度に基づいて行われます。例えば、軽度のアレルギー症状がある場合には、薬物療法や回避療法で十分な場合がありますが、重度のアレルギーや喘息を伴う場合には、免疫療法が必要になることがあります。 近年、アレルギー治療に関連した新しい技術やアプローチも開発されてきました。例えば、バイオ医薬品やモノクローナル抗体を使用した治療法があります。これらは、特定の免疫反応をターゲットにし、副作用を軽減しながら効果的に症状を抑えることを目的としたものです。 また、デジタルヘルス技術の進展により、アレルギーを持つ人々が自分の症状やアレルゲンについての情報を収集しやすくなっています。モバイルアプリやウェアラブルデバイスを使って、環境データや個人の症状を管理することが可能になり、より効果的な治療法の選択につながります。 さらに、アレルギーに関連する研究も進んでいます。最近の研究では、微生物叢（腸内細菌）とアレルギーの関係についての知見が深まっています。腸内細菌のバランスが免疫系に影響を与え、アレルギーの発症や重症化に関与している可能性が示されています。このため、プロバイオティクスやプレバイオティクスを用いた治療法も今後のアレルギー治療において期待される分野といえるでしょう。 アレルギー治療は今後ますます多様化し、個々のニーズに応じた治療法が提供されることが期待されます。求められる治療法の進展に合わせて、アレルギーを持つ人々がより快適な生活を送れるようになることが重要です。 |
❖ 世界のアレルギー治療市場に関するよくある質問(FAQ) ❖
・アレルギー治療の世界市場規模は？
→DataM Intelligence社は2023年のアレルギー治療の世界市場規模を250億3,000万米ドルと推定しています。
・アレルギー治療の世界市場予測は？
→DataM Intelligence社は2031年のアレルギー治療の世界市場規模を380億4,000万米ドルと予測しています。
・アレルギー治療市場の成長率は？
→DataM Intelligence社はアレルギー治療の世界市場が2024年～2031年に年平均5.4%成長すると予測しています。
・世界のアレルギー治療市場における主要企業は？
→DataM Intelligence社は「GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Stallergenes Greer, Allergy Therapeutics, Sanofi, Sumitomo Pharma Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc.など ...」をグローバルアレルギー治療市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
